Intravascular large B-cell lymphoma with primary bone marrow involvement – Report of a rare disease

Thapa, Samikshya; Tandon, Anchal; Hajra, Subhajit; Mishra, Sonali; UR, Kavya; Chandra, Aishwarya; Gupta, Arvind

doi:10.1016/j.htct.2022.04.003

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ki-67 is around 60% in tumor cells. [1] With this clinical picture, the diagnosis of intravascular large B cell lymphoma (IVLBL) was made. FDG PET/CT revealed diffusely increased uptake in the both axial and appendicular skeleton with (SUVmax 5.06) and diffusely increased FDG uptake (SUVmax 3.67) noted in the spleen.…”

Section: Differential Diagnosismentioning

confidence: 99%

A case of intravascular large B-cell lymphoma – Our clinical experience

Kumar

Hajra

Dhingra

et al. 2023

JHAS

Self Cite

View full text Add to dashboard Cite

Fever of unknown origin is always a diagnostic challenge in establishing etiology. A gentleman in his 70s presented with complaints of fever and dry cough for 2 months duration. We proceeded with contrast imaging of the thorax and abdomen which revealed mild hepatomegaly. Bone marrow examination with bone marrow culture and 18-fluorodeoxyglucose positron emission tomography/computed tomography (18-FDG PET/CT). Bone marrow aspirate smears were hypercellular with around 50% atypical lymphoid cells with plasmacytoid and bizarre morphology with few multilobed nuclei. Bone marrow biopsy revealed predominantly sinusoidal involvement by neoplastic cells. On immunohistochemistry, tumor cells were positive for CD45, CD79a, CD20, and MUM1 and were negative for CD5, CD10, and BCL6. Ki-67 was around 60% in tumor cells. FDG PET/ CT revealed diffusely increased uptake in the both axial and appendicular skeleton with (SUVmax 5.06) and diffusely increased FDG uptake (SUVmax 3.67) noted in the spleen. As intravascular large B-cell lymphoma is a highly aggressive non-Hodgkin lymphoma with a high risk of central nervous system involvement, we treated it with chemoimmunotherapy (R-CHOP) with intrathecal methotrexate. After a clinical follow of 3 months, the patient developed relapsed with a soft-tissue swelling over the right leg. The patient was treated with two cycles of R-DHAP and had progressive disease and started on Ibrutinib, Lenalidomide, and Rituximab (2 cycles). Post two cycles, the patient had progressive disease and switched to acalabrutinib based therapy. After 1 month of acalabrutinib-lenalidomide-rituximab therapy, the patient had disease progression and succumbed to the disease.

show abstract

Section: Differential Diagnosismentioning

confidence: 99%